Cracking the Code on a Successful Launch

Cracking the Code on a Successful Launch

Much like patient populations, successful launches come in all sizes.  Congratulations go to Regeneron this quarter on the success of the EYLEA® (aflibercept) Injection, which was approved by the FDA in November 2011 and is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), the key cause of blindness in the elderly.

As we announced earlier this year, CuraScript is among a limited number of specialty pharmacies and specialty distributors for EYLEA. 

Recently, Regeneron reported a 57% sales increase over its first quarter earnings and forecasted a 50% increase in sales for 2012.  In addition, Regeneron may be adding 110 jobs to meet this market growth.  At a time when budget and job cuts are in the news daily, this report is noteworthy.

Instrumental in EYLEA’s success was the decision by the Centers for Medicare and Medicaid Services (CMS) to issue a Q-code for EYLEA, effective July 1, 2012.  Q-codes uniquely identify a product and function in the same manner as a permanent billing code, creating greater efficiencies in the billing and reimbursement process for prescribers and their staff. Products often see a nice jump in sales after a Q-code is issued and company stock prices often increase as well.  Just as important, a Q-code designation helps get your product to your patients more quickly. 

As part of our services in support of EYLEA, CuraScript Specialty Distribution (CuraScript SD) implemented a multi-faceted campaign including outbound calls to physicians, fax and email communications, and physician pre-ordering to build awareness of the product within the ophthalmology community.

On behalf of all of us at CuraScript, congratulations to Regeneron and thanks for the opportunity to support EYLEA and its prescribers and patients.